Equities research analysts forecast that MacroGenics (NASDAQ:MGNX) will announce ($1.20) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Six analysts have issued estimates for MacroGenics’ earnings. The lowest EPS estimate is ($1.28) and the highest is ($0.94). MacroGenics reported earnings per share of ($1.14) during the same quarter last year, which would suggest a negative year-over-year growth rate of 5.3%. The firm is scheduled to announce its next earnings results on Wednesday, August 1st.
On average, analysts expect that MacroGenics will report full year earnings of ($4.74) per share for the current fiscal year, with EPS estimates ranging from ($5.32) to ($3.21). For the next year, analysts anticipate that the company will post earnings of ($4.10) per share, with EPS estimates ranging from ($5.57) to ($3.15). Zacks’ earnings per share averages are an average based on a survey of analysts that follow MacroGenics.
MacroGenics (NASDAQ:MGNX) last issued its quarterly earnings data on Monday, May 7th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the consensus estimate of ($1.08) by ($0.26). MacroGenics had a negative net margin of 19.64% and a negative return on equity of 13.03%. The company had revenue of $4.70 million for the quarter, compared to the consensus estimate of $7.46 million.
A number of analysts have recently commented on the stock. BidaskClub raised shares of MacroGenics from a “hold” rating to a “buy” rating in a research report on Wednesday, May 30th. Zacks Investment Research lowered shares of MacroGenics from a “buy” rating to a “hold” rating in a research report on Wednesday, May 9th. ValuEngine raised shares of MacroGenics from a “sell” rating to a “hold” rating in a research report on Thursday, March 1st. Leerink Swann reissued an “outperform” rating on shares of MacroGenics in a research report on Friday, April 6th. Finally, Wedbush reissued an “outperform” rating and issued a $44.00 price objective on shares of MacroGenics in a research report on Tuesday, May 8th. Four research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $30.89.
A number of institutional investors and hedge funds have recently modified their holdings of MGNX. SG Americas Securities LLC acquired a new position in MacroGenics during the first quarter worth $119,000. Alambic Investment Management L.P. acquired a new position in shares of MacroGenics in the first quarter valued at $215,000. Teacher Retirement System of Texas acquired a new position in shares of MacroGenics in the fourth quarter valued at $225,000. MetLife Investment Advisors LLC acquired a new position in shares of MacroGenics in the fourth quarter valued at $281,000. Finally, Citigroup Inc. increased its holdings in shares of MacroGenics by 61.4% in the first quarter. Citigroup Inc. now owns 13,564 shares of the biopharmaceutical company’s stock valued at $341,000 after purchasing an additional 5,162 shares during the last quarter. Institutional investors and hedge funds own 89.37% of the company’s stock.
Shares of MacroGenics opened at $21.25 on Monday, Marketbeat reports. The firm has a market cap of $965.16 million, a PE ratio of -39.35 and a beta of 2.45. MacroGenics has a 1 year low of $14.36 and a 1 year high of $32.74.
MacroGenics, Inc, a biopharmaceutical company, focuses on the discovery and development of antibody-based therapeutics for the treatment of cancer primarily by modulating the human immune system, as well as various autoimmune disorders and infectious diseases in the United States. The company's advanced clinical product candidate is Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets human epidermal growth factor receptor 2-expressing tumors, such as various breast and gastroesophageal cancers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.